# Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC

> **NCT01063283** · NA · COMPLETED · sponsor: **University of Chicago** · enrollment: 20 (actual)

## Conditions studied

- Advanced Non-squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab 7.5 mg/kg
- **DRUG:** Bevacizumab 15 mg/kg

## Key facts

- **NCT ID:** NCT01063283
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01063283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01063283, "Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01063283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*